Plasma glicentin in diabetic and gastrectomized patients

Regulatory Peptides

Volumn 79, Issue 1, 1999, Pages 55-61

  Naito, Hiroo ^a   Ohneda, Akira ^b   Kojima, Ryotaro ^c   Sato, Takeya ^c   Sasaki, Kazuyuki ^c   Funayama, Yuji ^a   Fukushima, Kouhei ^a   Shibata, Chikashi ^a   Matsuno, Seiki ^a   Sasaki, Iwao ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sen en General Hospital   (Japan)

^c NISSHIN SEIFUN GROUP INC   (Japan)

Author keywords

Diabetes mellitus; ELISA; Gastrectomy; Glicentin; Oral glucose; Short bowel

Indexed keywords

GLICENTIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRECTOMY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOASSAY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; TECHNIQUE;

BLOOD GLUCOSE; DIABETES MELLITUS; GASTRECTOMY; GLICENTIN; GLUCAGON; GLUCAGON-LIKE PEPTIDES; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0032920856     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00144-X     Document Type: Article

References (28)

1. Unger RH, Ketterer H, Eisentraut AM. Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism 1966;15:865-7.
2. Unger RH, Ohneda A, Valverde I, Eisentraut AM, Exton J. Characterization of the response of circulating glucagon-like immunoreactivity to intra-duodenal and intravenous administration of glucose. J Clin Invest 1968;47:48-65.
3. Sundby F, Jacobsen H, Moody AJ. Purification and characterization of a protein from porcine gut with glucagon-like immunoreactivity. Horm Met Res 1976;8:366-71.
4. Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept 1981;2:139-51.
5. Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982;79:345-9.
6. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-8.
7. Thim L, Moody AJ. Purification and chemical characterization of a glicentin-related pancretic peptide (proglucagon fragment) from porcine pancreas. Biochim Biophys Acta 1982;703:134-41.
8. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994;269:18827-33.
9. Buhl T, Thim L, Kofod H, Ørskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem 1988;263:8621-4.
10. Ørskov C, Buhl T, Rabenhoj L, Kofod H, Holst JJ. Carboxy-peptidase B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. FEBS Lett 1989;247:193-6.
11. Eisentraut AM, Ohneda A, Parada E, Unger RH. Immunologic discrimination between pancreatic glucagon and enteric glucagon-like immunoreactivity (GLI) in tissue and plasma. Diabetes 1968;17:321-2.
12. Ohneda A, Watanabe K, Wakimatsu M, Fujino M. Production of a specific antiserum by synthetic C-terminal fragment of glucagon. Horm Met Res 1979;11:463-8.
13. Imai S, Sasaki K, Satoh T, et al. Production of human glicentin in Escherichia coli. Biomed Res 1996;17:279-85.
14. Satoh T, Iguchi K, Mochizuki T, et al. Direct measurement of human glicentin in plasma by two-site immunoradiometric assay. Biomed Res 1996;17:141-8.
15. Bloom SR. An enteroglucagon tumor. Gut 1972;13:520-3.
16. Ohneda A, Ohneda K, Nagasaki T, Sasaki K. Insulinotropic action of human glicentin in dogs. Metabolism 1995;44:47-51.
17. Naito H, Sasaki I, Takahashi M, et al. Trophic effect of glicentin on intestinal mucosa during administration of elemental diet in rats. Biomed Res 1994;15(Suppl. 2):295-8.
18. Myojo S, Tsujikawa T, Sasaki M, Fujiyama Y, Bamba T. Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro. J Gastroenterol 1997;32:300-5.
19. Ohtani N, Sasaki I, Naito H, et al. Inhibitory effect of peptide YY, neurotensin and glicentin on upper gastrointestinal motility in dogs. Biomed Res 1994;15(Suppl. 2):299-302.
20. Ørskov C, Jeppensen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controis in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991;87:415-23.
21. Bilbey GL, Faloona GR, White MG, Knockel JP. Hyper-glucagonemia of renal failure. J Clin Invest 1974;53:841-7.
22. Kuku SF, Jaspan JB, Emmanouel DS, Zeidler A, Katz AI, Rubentein AH. Heterogeneity of plasma glucagon: Circulating components in normal subjects and patients with chronic renal failure. J Clin Invest 1976;58:742-50.
23. Heding LG. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 1971;7:10-9.
24. Rovira A, Garrote FJ, Pascual JM, Salvador MG, Herrena Pombo JL, Valverde I. Plasma glucagon and glucagon-like immunoreactive components in type I (insulin-dependent) diabetic patients and normal subjects before and after oral glucose load. Diabetologia 1985;28:80-6.
25. Ohneda A. Secretion of gut GLI and glicentin. Interdisciplinary Information Sciences 1995;1:177-90.
26. Ohneda A. Response of plasma glicentin to intraduodenal administration of glucose in piglets. Diabetes Res Clin Pract 1987;3:97-102.
27. Miholic J, Ørskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1(GLP-19), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991;36:1361-70.
28. Andreasen JJ, Ørskov C, Holst JJ. Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. Digestion 1994;55:221-8.